These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

990 related articles for article (PubMed ID: 25697677)

  • 41. Trends in multidrug-resistant gram-negative bacilli and the role of prolonged β-lactam infusion in the intensive care unit.
    Guervil DJ; Chau T
    Crit Care Nurs Q; 2013; 36(4):345-55. PubMed ID: 24002425
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Intravenous colistimethate (colistin) use in critically ill children without cystic fibrosis.
    Falagas ME; Sideri G; Vouloumanou EK; Papadatos JH; Kafetzis DA
    Pediatr Infect Dis J; 2009 Feb; 28(2):123-7. PubMed ID: 19116601
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinical translation of polymyxin-based combination therapy: Facts, challenges and future opportunities.
    Zhang X; Guo F; Shao H; Zheng X
    J Infect; 2017 Feb; 74(2):118-130. PubMed ID: 27998750
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Polymyxin Resistance Mechanisms: From Intrinsic Resistance to Mcr Genes.
    Meletis G; Skoura L
    Recent Pat Antiinfect Drug Discov; 2018; 13(3):198-206. PubMed ID: 30474535
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Shedding light on the use of colistin: still gaps to be filled].
    Luque S; Grau S; Berenguer N; Horcajada JP; Sorlí L; Montero MM; Salas E
    Enferm Infecc Microbiol Clin; 2011 Apr; 29(4):287-96. PubMed ID: 21440335
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Colonization and infection by colistin-resistant Gram-negative bacteria in a cohort of critically ill patients.
    Kontopidou F; Plachouras D; Papadomichelakis E; Koukos G; Galani I; Poulakou G; Dimopoulos G; Antoniadou A; Armaganidis A; Giamarellou H
    Clin Microbiol Infect; 2011 Nov; 17(11):E9-E11. PubMed ID: 21939468
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Rapid emergence of colistin resistance and its impact on fatality among healthcare-associated infections.
    Aydın M; Ergönül Ö; Azap A; Bilgin H; Aydın G; Çavuş SA; Demiroğlu YZ; Alışkan HE; Memikoğlu O; Menekşe Ş; Kaya Ş; Demir NA; Karaoğlan I; Başaran S; Hatipoğlu Ç; Erdinç Ş; Yılmaz E; Tümtürk A; Tezer Y; Demirkaya H; Çakar ŞE; Keske Ş; Tekin S; Yardımcı C; Karakoç Ç; Ergen P; Azap Ö; Mülazımoğlu L; Ural O; Can F; Akalın H;
    J Hosp Infect; 2018 Mar; 98(3):260-263. PubMed ID: 29248504
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Optimizing colistin dosing: Is a loading dose necessary?
    Nazer LH; Anabtawi N
    Am J Health Syst Pharm; 2017 Jan; 74(1):e9-e16. PubMed ID: 28007716
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A retrospective study on the effects of colistin therapy in children with multidrug-resistant Gram-negative bacterial pathogens: impact of HIV status on outcome.
    Dimitriades K; Morrow BM; Jeena P
    Arch Dis Child; 2014 Mar; 99(3):262-6. PubMed ID: 24170687
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Intravenous colistin sulphomethate sodium for therapy of infections due to multidrug-resistant gram-negative bacteria.
    Pintado V; San Miguel LG; Grill F; Mejía B; Cobo J; Fortún J; Martín-Dávila P; Moreno S
    J Infect; 2008 Mar; 56(3):185-90. PubMed ID: 18280570
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Molecular mechanisms of polymyxin resistance and detection of mcr genes.
    Mlynarcik P; Kolar M
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2019 Feb; 163(1):28-38. PubMed ID: 30439931
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Contemporary activity of colistin and polymyxin B against a worldwide collection of Gram-negative pathogens: results from the SENTRY Antimicrobial Surveillance Program (2006-09).
    Gales AC; Jones RN; Sader HS
    J Antimicrob Chemother; 2011 Sep; 66(9):2070-4. PubMed ID: 21715434
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Treatment Options for Carbapenem- Resistant Gram-Negative Infections.
    Fritzenwanker M; Imirzalioglu C; Herold S; Wagenlehner FM; Zimmer KP; Chakraborty T
    Dtsch Arztebl Int; 2018 May; 115(20-21):345-352. PubMed ID: 29914612
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Carbapenem and multidrug resistance in Gram-negative bacteria in a single centre in Italy: considerations on in vitro assay of active drugs.
    Mezzatesta ML; Caio C; Gona F; Cormaci R; Salerno I; Zingali T; Denaro C; Gennaro M; Quattrone C; Stefani S
    Int J Antimicrob Agents; 2014 Aug; 44(2):112-6. PubMed ID: 25059444
    [TBL] [Abstract][Full Text] [Related]  

  • 55. An update on the arsenal for multidrug-resistant Acinetobacter infections: polymyxin antibiotics.
    Kassamali Z; Jain R; Danziger LH
    Int J Infect Dis; 2015 Jan; 30():125-32. PubMed ID: 25461655
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Emergence of resistance to carbapenems in Acinetobacter baumannii in Europe: clinical impact and therapeutic options.
    Kempf M; Rolain JM
    Int J Antimicrob Agents; 2012 Feb; 39(2):105-14. PubMed ID: 22113193
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Is colistin effective in the treatment of infections caused by multidrug-resistant (MDR) or extremely drug-resistant (XDR) gram-negative microorganisms in children?
    Ozsurekci Y; Aykac K; Cengiz AB; Bayhan C; Sancak B; Karadag Oncel E; Kara A; Ceyhan M
    Diagn Microbiol Infect Dis; 2016 Jun; 85(2):233-8. PubMed ID: 27041107
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Carbapenem-resistant Gram-negative pathogens in a German university medical center: Prevalence, clinical implications and the role of novel β-lactam/β-lactamase inhibitor combinations.
    Katchanov J; Asar L; Klupp EM; Both A; Rothe C; König C; Rohde H; Kluge S; Maurer FP
    PLoS One; 2018; 13(4):e0195757. PubMed ID: 29649276
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Metallo-beta-lactamases in Gram-negative bacteria: introducing the era of pan-resistance?
    Maltezou HC
    Int J Antimicrob Agents; 2009 May; 33(5):405.e1-7. PubMed ID: 19095416
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Emerging broad-spectrum resistance in Pseudomonas aeruginosa and Acinetobacter baumannii: Mechanisms and epidemiology.
    Potron A; Poirel L; Nordmann P
    Int J Antimicrob Agents; 2015 Jun; 45(6):568-85. PubMed ID: 25857949
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 50.